METTL1 and cancer: GSEA analysis showed that genes of proliferation- and metastasis-related pathways were more likely to be enriched in high METTL1 expression cohorts in KIRC, LGG, and LIHC, demonstrating that METTL1 is a poor patient prognosis biomarker in these cancers and can be used to assess patient survival [88].